Abiopharma

News list

DOYLE THOMAS JAMES 🟢 acquired 63.8K shares (1 derivative) of Kura Oncology, Inc. (KURA) at $10.34 Transaction Date: Jan 02, 2026 | Filing ID: 004569

Full text

News bot Jan. 6, 2026, 10:32 p.m.
🔍 DOYLE THOMAS JAMES (Executive)

Company: Kura Oncology, Inc. (KURA)

Report Date: 2026-01-02
Transaction Summary:
- Total transactions: 3
- Derivative instruments: 1
- Holdings reported: 1
- Total shares acquired: 63,750
- Total shares held: 500
Detailed Transactions and Holdings:
- Acquired 21,250 shares of Common Stock (Direct)
  Date: 2026-01-02 | Code: A | equity_swap_involved: false | shares_owned_after: 152,309.00 | transaction_form_type: 4 | Footnotes: F1, F2
- Holds 0 shares of Common Stock (Direct)
  Date: 2026-01-02 | Code: H | nature_of_ownership: spouse's 401(k) | shares_owned_after: 500.00
- Acquired 42,500 shares of Option to purchase common stock at $10.335 per share (Derivative)
  Date: 2026-01-02 | Code: A | Expires: 2036-01-01 | equity_swap_involved: false | shares_owned_after: 42,500.00 | transaction_form_type: 4 | Footnotes: F3
Footnotes:
- F1: Grant of Restricted Stock Units (RSUs). The RSUs vest in four equal annual installments on 1/26/27, 1/26/28, 1/26/29 and 1/26/30.
- F2: Includes 802 shares acquired on November 17, 2025 pursuant to the Issuer's Employee Stock Purchase Plan.
- F3: This option vests in 48 equal monthly installments commencing on the grant date.